OR WAIT null SECS
The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
July 07, 2026
Article
This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.
July 06, 2026
This new analysis indirectly compares the clinical efficacy of risankizumab and icotrokinra in adults living with moderate-to-severe plaque psoriasis.
Video
This interview highlights both key findings and the significance of the POSITIVE trial for clinicians and for individuals with psoriasis.
This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.
June 30, 2026
Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.
June 29, 2026
FDA approves steroid-free roflumilast cream for plaque psoriasis in children age 2+, bringing once-daily option for sensitive areas.
FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.
June 25, 2026
Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.
June 17, 2026
DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.
June 12, 2026
This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.